Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 01/09

20090030178 - Cell permeable bioactive peptide conjugates: Cell permeable bioactive peptide conjugates having a first bioactive peptide region coupled to a second transport peptide region allowing transfer of the first bioactive peptide region and the second transport peptide region across biological membranes to enter intact living cells for regulation of biological responses.... Agent: Cr Miles, P.c. Craig R. Miles

20090030179 - Antimicrobial peptide and use thereof: Antimicrobial peptides provided by the present invention are artificially designed antimicrobial peptides that are not present in nature. Several antimicrobial peptides have, as the amino acid sequence related to the expression of antimicrobial property, a partial amino acid sequence in the α-domain of human-derived VHL protein. In addition, several antimicrobial... Agent: Amin, Turocy & Calvin, LLP

20090030180 - Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria: Several species of bacteria capable of invasive infections, such as S. pyogenes, S. equi and P. multocida, contain hyaluronic acid (HA) in their capsules. Bacterial species such as Staphylococcus aureus and related Staphylococci have capsules that contain acidic polysaccharides. Bacterial capsule or bacterial surface binding peptides were synthesized and tested... Agent: Ade & Company Inc.

20090030181 - Peptides for inhibiting mdm2 function: Disclosed are peptides for inhibiting mdm2 (mouse double minute 2) and a pharmaceutical composition comprising the same.... Agent: Kohn & Associates, Pllc

20090030182 - Activatable recombinant neurotoxins: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.... Agent: Allergan, Inc.

20090030183 - interferon beta-like molecules: The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid... Agent: Maxygen, Inc. Intellectual Property Department

20090030184 - Expression system for producing collagen: A DNA molecule consisting of the nucleotide sequence of SEQ ID NO: 1, which encodes a collagenous (COL1) domain and a C-terminal noncollagenous (NC1) domain of type XXI collagen. Expression systems and methods for the expression of the DNA molecule are also provided.... Agent: Birch Stewart Kolasch & Birch

20090030185 - Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins: A new approach in the field of plant gums is described which presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabino-galactan proteins (AGPs). The expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum... Agent: Dinsmore & Shohl LLP

20090030187 - Macromolecules comprising a thioether cross-link: The present invention provides macromolecules comprising at least one thioether cross-link. A thioether cross-link comprising a single thioether bond between two residues of a macromolecule. The macromolecules of the invention can display enhanced stability, pharmaceutical properties and functional properties. In particular, the invention provides an isolated antibodies comprising at least... Agent: Jones Day

20090030186 - Pichia methanolica secretory signal: Novel Pichia methanolica secretory signal polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods of using are disclosed. Methods of producing large amounts of recombinant proteins by employing DNA constructs having a polypeptide of interest preceded by a novel Pichia methanolica secretory signal sequence.... Agent: Zymogenetics, Inc. Intellectual Property Department

20090030188 - Activatable recombinant neurotoxins: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.... Agent: Allergan, Inc.

20090023892 - Enzymatic reactions in the presence of keto acids: Conversion in vitro of X-Gly to X-alpha-hydroxy-Gly or X-NH2 (X being a peptide or any other compound having a carbonyl group capable of forming a covalent bond with glycine) is accomplished enzymatically in the presence of keto acids, or salts or esters thereof, to provide a good yield without the... Agent: Ostrolenk Faber Gerb & Soffen

20090023893 - Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis: The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.... Agent: Knobbe Martens Olson & Bear LLP

20090023895 - Hla-binding peptide, precursor thereof, and dna fragment and recombinant vector coding for said hla-binding peptide: An HLA-binding peptide binding to an HLA-A type molecule is provided that includes one or more types of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 52, and not less than 8 and not more than 11 amino acid residues. All of these amino... Agent: Sughrue Mion, Pllc

20090023894 - Neutralizing antibody against hgf: The neutralizing antibody against HGF binding to the inventive neutralizable epitope of HGF is capable of neutralizing HGF as a single agent, and can be effectively used for preventing and treating intractable diseases and cancers that are caused by binding of HGF to its receptor Met.... Agent: Sughrue Mion, Pllc

20090023896 - Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds: This invention relates to compounds that as prodrugs and/or vehicles make it possible for an active ingredient to be taken up into erythrocytes and/or an active ingredient to bind to erythrocytes, whereby the uptake of the compounds into erythrocytes and/or the binding of the compounds to erythrocytes is made possible... Agent: Millen, White, Zelano & Branigan, P.c.

20090023897 - Method and apparatus for purifying and desalting biological samples: The subject invention provides a sample processing technique for purifying a biological or chemical sample. The invention is particularly well-suited to prepare a sample for mass spectrometry. The process is to be performed in an article having at least one well, in which the surface of the well is at... Agent: David W. Highet, Vp & Chief Ip Counsel Becton, Dickinson And Company

20090023898 - Methods and compositions for protein purification: The present invention provides methods of purifying proteins that include a metal ion affinity peptide. The methods generally involve contacting a fusion protein that includes a metal ion affinity peptide with at least two different metal ion chelating resins. In certain representative embodiments, the methods include contacting a fusion protein... Agent: Bozicevic, Field & Francis LLP

20090023899 - Defatting collagen: Pig rind is one source of collagen for processing into products, such as sausage casings and films. However, it has a high fat content. The invention produces a defatted collagen paste from a collagen source by cutting the collagen into pieces, pressurising the collagen pieces to squeeze out fat and... Agent: Myers Bigel Sibley & Sajovec

20090023900 - Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same: The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to αvβ3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Additionally provided are methods of inhibiting a function of αvβ3 by contacting αvβ3 with an enhanced LM609 grafted antibody.... Agent: Mcdermott, Will & Emery

20090023901 - Degradable clostridial toxins: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a... Agent: Allergan, Inc.

20090023902 - Method for the extraction of intracellular proteins from a fermentation broth: A method for extracting an intracellular peptide, protein or other polypeptide from a whole fermentation broth using a water miscible alcohol, or a water miscible or partially water miscible glycol ether.... Agent: The Dow Chemical Company

20090018310 - Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition: The invention relates to peptides and peptide derivatives of the following general Formulas (Ia) and (Ib) as well as in particular anti-inflammatory drugs containing these peptides.... Agent: Birch Stewart Kolasch & Birch

20090018311 - Methods and compounds for producing dipeptidyl peptidase iv inhibitors and intermediates thereof: Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP Bristol-myers Squibb

20090018312 - Igf-1 receptor interacting proteins: The invention comprises a nucleic acid molecule with the sequence SEQ ID NO:5 and the complementary sequence, and its use in diagnosis and therapy. This nucleic acid molecule (IIP-10) is a gene which encodes an IGF-1 receptor binding polypeptide.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090018313 - Enhanced production of blood clotting factors and fibrin fabric: The blood collection, processing and transfer by separation of discrete components containing additional citrate (at least about trisodium citrate 9% w/v) in one or other of collection or processing bag provides for enhanced yield and purity of cryoprecipitate. Inhibiting the activation or denaturation of blood components including blood cells and... Agent: Stefan Kirchanski

20090018314 - Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090018315 - B7-h3 and b7-h4, novel immunoregulatory molecules: The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.... Agent: Fish & Richardson P.C.

20090018316 - Interleukin-15 receptors: There are disclosed Interleukin-15 Receptor (IL-15R) proteins, DNAs and expression vectors encoding IL-15R, and processes for producing IL-15R as products of recombinant cell cultures.... Agent: Immunex Corporation Law Department

20090012261 - Hla epitope identification: The present invention describes ways to identify HLA allele-specific epitopes that result from HLA restriction of antigen-specific cellular immune responses. The invention employs a combination of bioinformatics and functional assays to systematically identify and classify CTL mutations to determine correlates of virus-host interactions Peptides representing HLA allele-specific epitopes are provided... Agent: Ade & Company Inc.

20090012262 - Forisomes, method for their isolation, and their use as a molecular working machine: A protein body derivable from Fabaceae has a reversible, anisotropic contractability such that the protein body becomes thicker perpendicular to a longitudinal axis of the protein body and shorter along the longitudinal axis of the protein body when increasing a calcium ion concentration in a medium surrounding the protein body... Agent: Gudrun E. Huckett Draudt

20090012263 - Process for production of (1,3-disubstituted indolyl)-urea derivatives, intermediates therefor, and process for production of the intermediates: A process for the production of (1,3-disubstituted indolyl) urea derivatives represented by the general formula (1), characterized by reacting a 1-substituted-aminoindole derivative with a phenyl halocarbonate to form a carbamate derivative, subjecting the carbamate derivative to Mannich reaction with a secondary amine and formaldehyde to form a 3-aminomethylindole derivative represented... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090012264 - Microwave-assisted peptide synthesis: An instrument and method for accelerating the solid phase synthesis of peptides is disclosed. The method includes the steps of deprotecting a protected first amino acid linked to a solid phase resin by admixing the protected linked acid with a deprotecting solution in a microwave transparent vessel while irradiating the... Agent: Summa, Allan & Additon, P.A.

20090012265 - Purification of polymers carrying a lipophilic group: This invention relates to a method of producing a purified polymer selected from the group consisting of PNAs, (poly)peptides, PNA chimera, peptide-DNA chimera, and derivatives thereof, wherein the polymer carries at least one lipophilic group and wherein the method comprises the following steps: (a) transferring a solution comprising the polymer... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090012266 - Anti-tnfalpha antibodies and methods of use: Novel TNFα antibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to treat TNFα-related diseases are also disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20090012267 - Anti-hydroxylase antibodies and uses thereof: Antibodies, or antigen-binding portions thereof, to aspartyl (asparaginyl) β-hydroxylase are provided. The anti-aspartyl (asparaginyl) β-hydroxylase antibodies, or antigen-binding portions thereof, can modulate activity of aspartyl (asparaginyl) β-hydroxylase.... Agent: Fish & Richardson PC

20090012269 - Humanized anti-ccr2 antibodies and methods of use therefor: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of... Agent: Lowrie, Lando & Anastasi, LLP

20090012268 - Novel monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine: Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab′)2, Fab or Fv) or humanized forms of such monoclonal antibodies or single chain forms (SCA; scFv) of such fragments, which... Agent: Heslin Rothenberg Farley & Mesiti PC

20090012270 - Ox2 receptor homologs: Nucleic acids encoding mammalian, e.g., primate, receptors, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.... Agent: Morrison & Foerster LLP

20090012271 - Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies,... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090012272 - Modified fc molecules: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.... Agent: Amgen Inc.

20090012273 - Method of regenerating elastic fiber with the use of dance or factor enhancing the expression thereof: The present invention provides a technique for conveniently and efficiently regenerating elastic fiber retaining a normal structure, and a technique enabling preparation of an artificial tissue comprising elastic fiber (for example, artificial skin, artificial blood vessels) that can be transplanted to humans. Specifically, the invention provides a method of producing... Agent: Stephen B. Shear Patent Department, Plaza I

20090012275 - Means and methods for mediating protein interference: The invention belongs to the field of functional proteomics and, more particularly, to the field of protein aggregation. Described are methods for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and that induces... Agent: Trask Britt

20090012274 - Unsaturated aldehyde surfaces and methods of molecular immobilization: e

20090005534 - Methods and compositions for the treatment of gastrointestinal disorders: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic... Agent: Fish & Richardson PC

20090005535 - Solution-phase synthesis of leuprolide and its intermediates: The invention relates to a process for producing the nonapeptide leuprolide and the intermediate N-protected oligopetides thereof, wherein at least one peptide bond of the compound is formed by reacting an activated carboxylic acid and an amine component in a continuous flow.... Agent: Demont & Breyer, LLC

20090005536 - Hybrid solid supports useful for oligonucleotide production: A method for preparing a crosslinked polymer coated controlled porosity glass (CPG) particle is provided. The method involves mixing CPG particles in a solution comprising polyvinylbenzylchloride and a first solvent at a temperature below 10° C. A second solvent is added and a crosslinking agent is added to the mixture.... Agent: Howson And Howson

20090005538 - Apoptosis-inducing agent for prostate cancer cells: m

20090005537 - Process for constructing strain having compactin hydroxylation ability: The present invention is directed to methods and compositions for microbial based production of pravastatin. The compositions of the invention include novel strains of microorganisms that are capable of efficiently hydroxylating compactin (ML-236 B) resulting in production of pravastatin. In particular, the microorganisms of the invention are genetically engineered to... Agent: Kenyon & Kenyon LLP

20090005539 - Additives for the improved dewatering of corn gluten: The invention relates to a method of dewatering corn gluten stream wherein coagulant is add to the corn gluten stream of the corn wet milling process. The method of dewatering corn gluten uses an effective amount of a coagulant of one or more anionic polymers, the anionic polymers comprising one... Agent: Nalco Company

20090005540 - Method for removing sialic acid and method for producing asialoerythropoietin: The object is to provide a method for removing a sialic acid that can be carried out simply at a low cost and a method for producing asialoerythropoietin using the same. The method for removing a sialic acid according to the present invention includes an acidifying and heating process of... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090005541 - Gag binding protein: e

20090005542 - Hydrolysable polymeric fmoc- linker: The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.... Agent: Baxter Healthcare Corporation

20090005543 - Protein-refolding material: The present invention provides a method for refolding protein produced, for example, by Escherichia coli, that is inactive due to an as yet unformed higher order structure, or protein deactivated due to a change in conformation for some reason. The invention comprises a method, refolding kit, refolding agent, and molding... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090005544 - Process for making soy protein isolates: Disclosed is a process comprising: mixing a soy protein-containing material with an aqueous medium; removing the non-solubilized solids from the slurry to form an alkaline liquid containing solubilized soy protein; adjusting the pH of the solubilized soy protein liquid to between about 3.8 and about 6.6, to precipitate soy protein... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1